FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
From: .google.com The FDA has approved imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative,...